The Dual Approach: Treating Infection and Resetting the Immune System
At a Glance
Treating Adult-Onset Immunodeficiency (AOID) requires a dual approach. First, long-term antibiotics are used to aggressively clear active infections like NTM. Second, targeted therapies like rituximab stop harmful autoantibodies, which unblocks the immune system so it can protect the body.
Managing Adult-Onset Immunodeficiency (AOID) requires more than just standard antibiotics. Because the condition is caused by an “autoimmune block” that prevents your immune cells from working, doctors must use a dual-pronged approach to help you heal [1][2].
This strategy involves two different goals: clearing the germs currently in your body and “unmuting” your immune system so it can protect you in the future.
Prong 1: Targeted Antimicrobial Therapy
The first step is to aggressively treat any active infections, such as Nontuberculous Mycobacteria (NTM), Salmonella, or fungal infections like Talaromyces [3].
- The Timeline: NTM infections are notoriously slow to clear. You should expect to stay on a complex combination of antibiotics for 12 to 18 months after your cultures finally turn negative [4].
- Side Effects and Monitoring: Long-term antibiotics for NTM (like ethambutol or rifamycins) carry real risks. They can cause optic neuritis (vision changes or loss) and hepatotoxicity (liver strain) [5]. You will need regular liver function blood tests and routine eye exams to catch any side effects early [6]. Report any changes in your vision or severe fatigue immediately.
Prong 2: Immunomodulatory Therapy
The second step addresses the root cause: the autoantibodies blocking your immune signals.
- The Immunosuppressant Paradox: It can sound completely backwards and terrifying to take an “immunosuppressant” drug when your body is already overrun by severe infections. However, treatments like rituximab are highly targeted. They specifically deplete B-cells, the exact factory making your harmful autoantibodies [1]. By shutting down this “bad factory,” Rituximab removes the gum from the lock. This allows the rest of your immune system (your macrophages) to turn back on and finally kill the germs [7].
- Safety Precautions: Because Rituximab lowers your B-cells, you will have less protection against common viruses. You should practice rigorous hygiene, consider masking in crowded indoor spaces, and wash hands frequently while your B-cells are depleted [3].
- Other Options and Warnings: While medications like cyclophosphamide or azathioprine are sometimes mentioned, these are broad, heavy immunosuppressants. They are strictly reserved for severe, highly refractory cases because they carry a very high risk of worsening your existing opportunistic infections [8].
Building Your Care Team
Because AOID is both an infectious disease problem and an autoimmune problem, your care should be a team effort. Most patients require:
- Infectious Disease (ID) Specialist: To manage the complex, long-term antibiotic or antifungal regimens.
- Immunologist or Rheumatologist: To manage the B-cell depletion and therapies that “reset” the immune system.
By using this two-pronged strategy—fighting the germs while simultaneously removing the “autoimmune block”—many patients are able to achieve long-term remission and return to a higher quality of life [3].
Common questions in this guide
Why do I need an immunosuppressant like rituximab if I have severe infections?
How long will I need to take antibiotics for my NTM infection?
What side effects should I watch for while on long-term antimicrobial therapy?
What precautions should I take while on B-cell depletion therapy?
Which specialists need to be on my AOID care team?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.What is our long-term timeline for both treating my current infections and reducing my anti-IFN-gamma autoantibody levels?
- 2.If we start Rituximab, how often will you monitor my B-cell counts and autoantibody titers?
- 3.What specific side effects (like vision changes or liver strain) should I be watching for with my antimicrobial medications, and how often will I need blood or eye tests?
- 4.What daily precautions should I take (like masking or avoiding crowds) while my B-cells are depleted?
- 5.Since this requires coordination between different types of doctors, how will my Infectious Disease specialist and Immunologist communicate about my care?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (8)
- 1
Anti-IFN-γ Autoantibody Syndrome Presenting with Disseminated Nontuberculous Mycobacteria Infections: A Case Series of Therapeutic Implications and Review of Literature.
Cheng B, Bajwa B, Choi S, et al.
Tropical medicine and infectious disease 2025; (10(7)) doi:10.3390/tropicalmed10070202.
PMID: 40711078 - 2
Clinical outcome and laboratory markers for predicting disease activity in patients with disseminated opportunistic infections associated with anti-interferon-γ autoantibodies.
Angkasekwinai N, Suputtamongkol Y, Phoompoung P, et al.
PloS one 2019; (14(4)):e0215581 doi:10.1371/journal.pone.0215581.
PMID: 31022229 - 3
Natural History and Evolution of Anti-Interferon-γ Autoantibody-Associated Immunodeficiency Syndrome in Thailand and the United States.
Hong GH, Ortega-Villa AM, Hunsberger S, et al.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2020; (71(1)):53-62 doi:10.1093/cid/ciz786.
PMID: 31429907 - 4
A case report of Talaromyces marneffei Oro-pharyngo-laryngitis: a rare manifestation of Talaromycosis.
Wongkamhla T, Chongtrakool P, Jitmuang A
BMC infectious diseases 2019; (19(1)):1034 doi:10.1186/s12879-019-4650-7.
PMID: 31805893 - 5
Endobronchial Lesions from Disseminated Mycobacterium avium Infection in a Patient with Anti-interferon-gamma Autoantibodies.
Mochizuka Y, Kono M, Hirama R, et al.
Internal medicine (Tokyo, Japan) 2021; (60(20)):3267-3272 doi:10.2169/internalmedicine.6693-20.
PMID: 33896863 - 6
Disseminated Mycobacterium haemophilum skeletal disease in a patient with interferon-gamma deficiency.
Otome O, O'Reilly M, Lim L
Internal medicine journal 2015; (45(10)):1073-6 doi:10.1111/imj.12875.
PMID: 26429217 - 7
Rituximab Restores IFN-γ-STAT1 Function and Ameliorates Disseminated Mycobacterium avium Infection in a Patient with Anti-Interferon-γ Autoantibody.
Koizumi Y, Sakagami T, Nishiyama N, et al.
Journal of clinical immunology 2017; (37(7)):644-649 doi:10.1007/s10875-017-0425-3.
PMID: 28779413 - 8
Intravenous Cyclophosphamide Therapy for Anti-IFN-Gamma Autoantibody-Associated Mycobacterium abscessus Infection.
Chetchotisakd P, Anunnatsiri S, Nanagara R, et al.
Journal of immunology research 2018; (2018()):6473629 doi:10.1155/2018/6473629.
PMID: 30687765
This information explains general treatment strategies for Adult-Onset Immunodeficiency (AOID) for educational purposes. Always consult your infectious disease specialist or immunologist regarding your specific antimicrobial or immunosuppressant regimen.
Get notified when new evidence is published on Adult-onset immunodeficiency with anti-interferon-gamma autoantibodies.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.